| 2.96 -0.01 (-0.34%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.86 | 1-year : | 4.42 |
| Resists | First : | 3.31 | Second : | 3.78 |
| Pivot price | 3.16  |
|||
| Supports | First : | 2.53 | Second : | 2.11 |
| MAs | MA(5) : | 3.18 |
MA(20) : | 3.11 |
| MA(100) : | 7.86 |
MA(250) : | 8.67 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 33.8 |
D(3) : | 48.7 |
| RSI | RSI(14): 38.6 |
|||
| 52-week | High : | 14.22 | Low : | 2.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VSTM ] has closed above bottom band by 33.9%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.16 - 3.18 | 3.18 - 3.19 |
| Low: | 2.89 - 2.9 | 2.9 - 2.91 |
| Close: | 2.94 - 2.96 | 2.96 - 2.98 |
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Fri, 26 Jul 2024
B. Riley Weighs in on Verastem, Inc.'s Q3 2024 Earnings (NASDAQ:VSTM) - MarketBeat
Fri, 26 Jul 2024
Short Interest in Verastem, Inc. (NASDAQ:VSTM) Grows By 77.3% - Defense World
Wed, 24 Jul 2024
Verastem Inc. hits 52-week low, trading at $2.59 - Investing.com
Wed, 24 Jul 2024
Verastem Oncology slumps 26%, prices $55M offering (NASDAQ:VSTM) - Seeking Alpha
Tue, 23 Jul 2024
Bragar Eagel & Squire, P.C. Is Investigating Verastem, - GlobeNewswire
Mon, 15 Jul 2024
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 66.9 (%) |
| Shares Short | 1,280 (K) |
| Shares Short P.Month | 2,380 (K) |
| EPS | -4.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.99 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.6 % |
| Return on Equity (ttm) | -210.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -94 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -0.7 |
| PEG Ratio | -0.5 |
| Price to Book value | 2.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|